Hopes are rising that a Covid-19 vaccine is within reach, following reports that an interim study .
Drug manufacturers Pfizer and BioNTech have claimed that their vaccine candidate is “more than 90% successful in preventing COVID-19” in people who have not been recently infected with the virus as far as they know. But it is not yet at the end of the race.
Two jabs, each three weeks apart, are involved in the vaccine, called BNT162b2.
94 lab-confirmed COVID-19 infections were identified in preliminary results from the company’s phase 3 clinical trial, which began in July and has more than 43,000 registered participants.
The Pfizer trial is one of four possible vaccines that, if it is efficient, the Australian Government has negotiated an agreement to buy.
As of now, there are no safety issues regarding the vaccine, with no significant side effects documented by the two firms.
The high proportion of those who are covered makes it extremely convincing.
Vaccine effectiveness of Pfizer / BioNtech’s COVID-19 vaccine is determined by clinical trials.
In the real world, the efficacy of vaccinations is assessed after the vaccine is approved for use in the general population.
According to the company’s report, the vaccine worked much better than most analysts had wished for, and brings into focus a possible end to a pandemic that has destroyed more than a million people, battered economies and upended everyday life globally.